Ken Griffin Esperion Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $550 Billion
- Q2 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 2,329,133 shares of ESPR stock, worth $4.17 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,329,133
Previous 100,800
2210.65%
Holding current value
$4.17 Million
Previous $145,000
1473.79%
% of portfolio
0.0%
Previous 0.0%
Shares
32 transactions
Others Institutions Holding ESPR
# of Institutions
183Shares Held
106MCall Options Held
139KPut Options Held
604K-
Black Rock Inc. New York, NY14MShares$25 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$21 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT10.3MShares$18.5 Million0.05% of portfolio
-
Two Seas Capital LP Rye, NY9.95MShares$17.8 Million0.18% of portfolio
-
Pender Fund Capital Management Ltd. Vancouver, A16.68MShares$12 Million4.26% of portfolio
About Esperion Therapeutics, Inc.
- Ticker ESPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,551,600
- Market Cap $119M
- Description
- Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...